MICROPORT NEURO's stock price surged 5.02% during intraday trading on Tuesday.
The significant rise follows positive sector news highlighting China's advancement in brain-computer interface (BCI) technology. A pioneering clinical trial for a 128-channel fully implantable BCI system was officially launched, marking a key step towards clinical translation and commercialization. Furthermore, a recent market report projects the Chinese BCI market to exceed 5 billion yuan by 2026, entering a "golden window" for large-scale application. MICROPORT NEURO was specifically cited as a related concept stock due to its leading position in China's neurointerventional medical device market, which is closely tied to the neurological field targeted by BCI innovations.
Comments